{
    "nct_id": "NCT03178552",
    "official_title": "A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)",
    "inclusion_criteria": "* Histologically or cytologically confirmed diagnosis of unresectable Stage IIIb not amenable to treatment with combined modality chemoradiation (advanced) or Stage IV (metastatic) NSCLC\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2\n* Measurable disease\n* Adequate recovery from most recent systemic or local treatment for cancer\n* Adequate organ function\n* Life expectancy greater than or equal to (>/=) 12 weeks\n* For female participants of childbearing potential and male participants, willingness to use acceptable methods of contraception\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Inability to swallow oral medication\n* Women who are pregnant or lactating\n* Symptomatic, untreated CNS metastases\n* History of malignancy other than NSCLC within 5 years prior to screening with the exception of malignancies with negligible risk of metastasis or death\n* Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to randomization, unstable arrhythmias, or unstable angina\n* Known active or uncontrolled human immunodeficiency virus (HIV) infection\n* Either a concurrent condition or history of a prior condition that places the patient at unacceptable risk if he/she were treated with the study drug or confounds the ability to interpret data from the study\n* Inability to comply with other requirements of the protocol",
    "miscellaneous_criteria": ""
}